MetaCap

Edesa Biotech (EDSA) vs Nasus Pharma (NSRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Edesa Biotech (EDSA) has outperformed Nasus Pharma (NSRX) over the past year, gaining 17.6% versus a loss of 68.4%. Edesa Biotech is the larger company by market cap ($27.0 million vs $26.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EDSA+17.65%NSRX-68.41%
+1028%+452%-125%
Nov 21, 20251 yearNov 20, 2026
EDSA-10.71%NSRX-71.73%
+723%+306%-111%
Aug 11, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EDSA versus NSRX key metrics
MetricEDSANSRX
Share price$2.00$2.29
Market cap$27.02M$26.82M
1-day change-8.05%-10.20%
YTD return+40.85%-74.97%
1-year return+17.65%-68.41%
5-year return-95.63%—
EPS (TTM)$-1.72$-1.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.24B
Net income (latest FY)$-7.19M$-5.86M
Operating margin—-0.40%
Net margin—-0.47%
52-week high$20.32$9.50
52-week low$0.72$1.98
Distance from 52-week high-90.16%-75.89%
Analyst consensusnonebuy
Avg. price target upside+716.50%+758.95%
Average volume1.45M16.80K
Shares outstanding13.51M11.71M
Employees177
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EDSA has outperformed NSRX by 86.1 percentage points over the past year.

About Edesa Biotech

EDSA stock →

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About Nasus Pharma

NSRX stock →

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

EDSA vs NSRX FAQ

Which is bigger, Edesa Biotech or Nasus Pharma?

Edesa Biotech (EDSA) is larger, with a market capitalization of $27.02M compared with $26.82M for Nasus Pharma (NSRX).

Which stock has performed better over the past year, EDSA or NSRX?

EDSA returned +17.65% over the past 12 months, compared with -68.41% for NSRX (price return, excluding dividends). Past performance does not predict future results.

Are Edesa Biotech and Nasus Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons